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Genetic Renal Disease (GRD) presents to mainstream clinicians as a mixture of kidney-specific as well as multi-organ
entities, many with highly variable phenotype-genotype relationships. The rapid increase in knowledge and reduced
cost of sequencing translate to new and additional approaches to clinical care. Specifically, genomic technologies
to test for known genes, the development of pathways to research potential new genes and the collection of
registry data on patients with mutations allow better prediction of outcomes. The aim of such approaches is to
maximise personal and health-system utility from genomics for those affected by nephrogenetic disorders.
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Chronic kidney disease (CKD) in paediatric and adult
populations produces a significant burden of morbidity
and mortality [1] and frequently has a genetic aetiology
[2]. However, Genetic Renal Disease (GRD) itself repre-
sents a heterogeneous and poorly defined group of, often
rare, disorders. GRD is the cause for 10 % of kidney dis-
ease in adult renal practice [3] and up to 10–15 % and
50 %, respectively, of adults and children commencing
dialysis [4]. The emergence of genomic technologies pre-
sents opportunities for better delineation of these condi-
tions and for further gene discovery, thus overcoming
genetics exceptionalism to enable optimised clinical care
and providing the opportunity to develop targeted ther-
apies. To realise this potential for patients, families and
their physicians, managing increasing volumes and com-
plexity of genetic and clinical information requires a
multifaceted novel approach.Main text
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(RGCs) have been established, there is little data on the
specific models employed. RGCs attempt to provide a
better way for patients and families with rare nephroge-
netic diseases in accessing appropriate diagnostics,
useful disease-specific information, genetic counselling,
and highly specialised therapies in a centralised patient-
focussed approach.
Currently, these clinics are located in tertiary hospitals,
accessible to patients with rare/genetic diseases, with
specialised nephrologists with genetic training and clin-
ical geneticists, genetic counsellors, specialised nurses
and allied health with whom to operate combined
clinics. Additionally, RGCs need close contact with diag-
nostic laboratories and scientists. Such multidisciplinary
clinics are increasingly necessary for delivering care in
rare genetic disease [6]. Examples include ophthalmol-
ogy, cardiology, oncology, hepatology, neurology and
otolaryngology. These innovative clinical models have
been encouraged as part of health service delivery
reorganisation to deliver more patient-focussed care [7].
Successful models share in common an interaction
between clinical geneticists, sub-specialists, genetic
counsellors, speciality nursing staff and other allied
health staff with ongoing collaborations with molecular
geneticists and scientists. One challenge is a general lack
of sub-specialised professional staff; however, targeted
training and education are likely to overcome this in the
medium-long term. Another challenge is patient transitionrticle distributed under the terms of the Creative Commons Attribution License
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ied by active involvement of paediatric nephrologists
within the RGC in order to provide lifespan and whole
family care. A third potential challenge is the pitfalls asso-
ciated with genetic testing, including pre-symptomatic
testing in at-risk individuals, prenatal diagnostics, non-
paternity/maternity and medically actionable incidental
findings in whole exomic or genomic sequencing. Within
the RGC, patient consultation with clinical geneticists and
genetic counsellors is ideally placed as a standard-of-care
to minimise such risks whilst maximising patient benefit
and support. Further, additional specialists are required
for GRDs with extra-renal involvement, such as oncolo-
gists and endocrinologists for WT1 disorders, metabolic
physicians and neurologists for mitochondrial disorders
and hepatologists and ophthalmologists for ciliopathies.
Supportive medical administrators and molecular geneti-
cists enhance the model further. An RGC should be no
different, with natural implications for broader patient
management such as medical interventions, therapies and
genetic counselling.
GRDs are phenotypically diverse and attributed to
growing numbers of known genes, with increasingly
complex phenotype-genotype relationships. Genomics
enables rapid diagnosis of mutations in known nephro-
genes. This includes very efficient sequencing of many
known genes simultaneously and effectively for ciliopa-
thies [8], podocytopathies and glomerular disease [9, 10],
complement dysregulopathies [11], congenital abnormal-
ities of the kidney and urinary tract (CAKUT) [12],
tubular disease and nephrocalcinosis/nephrolithiasis
[13]. This may be via whole exome or genome sequen-
cing, or targeted and prioritised gene panel screening of
these. For several diagnoses, precise genetic diagnosis
drives therapeutic decisions. Examples of this include
steroid-resistant nephrotic syndrome where therapies
with significant side-effect profiles are unlikely to be
effective, Alport syndrome in which the early instigation
of renin-angiotensin system blockade may delay renal
dysfunction progression and atypical haemolytic uraemic
syndrome in which some genotypes (CFH) are associated
with more pressing requirements for eculizumab or
combined liver-kidney transplantation whilst others (C5,
DGKE, MMACHC) may confer altered responses to
medical therapy. There are also indirect and surprising
findings. For instance, where 12 genes are responsible
for only 6 % of unselected paediatric CAKUT cases [12],
14 genes are causative for 15 % of similarly unselected
nephrolithiasis/nephrocalcinosis [13]. Intriguingly, CAKUT
is a common paediatric nephropathy of potentially and
well-recognised genetic aetiology, where nephrolithiasis/
nephrocalcinosis is a common adult renal presentation of
potentially though “rare” genetic aetiology. Genomics is
altering prevailing concepts of kidney disease, includingdiagnosis and therapy, whilst translating to changes in
nephrological practice.
Amongst other applications, genomics has also opened
the frontier to discovery of undescribed causative genes.
A genomic approach provides a research pathway to
discovery in those with individually rare undiagnosed
GRDs. For example, the identification of a specific
LMX1B mutation associated with a renal-limited rather
than multisystem form of Nail-Patella syndrome [14]
challenges classical phenotype-genotype relationships.
Other examples include the findings of podocyte-related
gene mutations in some patients with histological mem-
branoproliferative glomerulonephritis [10], mutations in
a ciliary gene (TTC21B) causing focal segmental glomer-
ulosclerosis [15] and mutations in a recently described
gene (DGKE) resulting in atypical haemolytic uraemic
syndrome [16], membranoproliferative glomeruloneph-
ritis [17] and steroid-resistant nephrotic syndrome [10].
Similarly, the discovery of mutations in DNA damage re-
pair genes (ZNF423; CEP164) causing nephronophthisis
[18] expands pathophysiological understanding. Such
advances have potential implications for future directed
approaches to treatment, as these are likely to be under-
pinned by accurate understanding of disease pathogenesis.
The autosomal recessive spectrum of nephronophthisis
and related ciliopathies continues to present promising
opportunity for gene discovery utilising genomic tech-
nologies [19–21], a necessary prequel to translational
proteomics [22].
There are many specific examples of the rapidly expand-
ing diagnostic success of massively parallel sequencing
(MPS). An instance has been Autosomal Dominant
Tubulointerstitial Kidney Disease, a subset of which was
chronically refractory to MPS [23] though subsequently
found to be due to specific MUC1 mutations. Further,
accurate genomic sequencing is notoriously difficult for
Autosomal Dominant Polycystic Kidney Disease (PKD1
and PKD2 mutations) due to homology with pseudogenes
[24]. This assumes significance as this is the most com-
mon potentially lethal monogenic inherited disease
amongst humans. Whilst genetic approaches have over-
come these obstacles for diagnostic purposes [25, 26], they
highlight that genomic studies may not always adequately
resolve specific GRDs and that one needs to be cognisant
of technological limitations, including copy number varia-
tions [27], read depth, coverage of regions of interest, a
relative lack of bioinformaticians in the healthcare system
and incomplete knowledge. The utilisation of family-based
bioinformatics, such as trios, in genomic studies for gene
discovery and diagnosis [28] appears crucial, especially
when a complex clinical phenotype has not been appreci-
ated [29].
For many GRDs, only a fraction of the genetic causes
is known. There are three major issues that dominate
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the increasing heterogeneity of phenotypes linked to
genes, secondly, many clinical phenotypes have numer-
ous differing genetic and undiagnosed causes, and
thirdly, frequent extra-renal organ involvement in GRDs.
Whilst many genetic causes can be identified, variants of
uncertain significance may be found. In such cases,
intra-family segregation analysis or functional study of
such variants in pre-clinical non-human, fibroblast, or
autologous self-organising renal organoid model systems
[30] may be utilised to clarify variant significance.
Families and individuals in whom a genetic cause seems
likely can then be directed into discovery programmes
to illuminate their disease. Therefore, this increasingly
variable and rapidly changing field now needs a co-
ordinated team approach linking patients, clinicians and
scientists. This may have health economic benefits
within the context of increased uptake of emerging
genomic technologies in the RGC, whilst due caution is
required with regard to local legislative, regulatory,
health funding and insurance environments.
A recent Norwegian population study suggests that
the magnitude of undiagnosed GRD may be as large as
diagnosed GRD [31]. These findings highlight the
importance of epidemiological and registry studies as an
adjunct to genomic diagnostics or discovery studies.
Epidemiological investigation is critical to describe and
target nephrogenetic conditions for investigation utilis-
ing genomic technologies. Particularly to prevent confu-
sion when disease or genotype frequency estimations
reported for single-centre or highly selected cohorts [32]
have resulted in over-estimation. This becomes apparent
when large multicenter cohorts are further examined
[12] or when interrogation of such cohorts for highly
defined phenotypes is undertaken [33].
Conclusions
In conclusion, an initial step for nephrogenetic clinical
translation is to progress a conversation defining
patient-centric priorities within a changing context of
clinical care and genomic technologies. We postulate
that this involves reconceptualising clinical interfaces,
applying such genomics for clinical diagnosis of known
nephrogenes, utilising genomics in research to discover
new genetic aetiologies and furthering epidemiological
investigation of GRD. The RGC is a proposed multidis-
ciplinary construct potentially capable of incorporating
and actioning such changes. The aim of such an
approach is to maximise personal and health-system
benefit from genomics for those affected by nephroge-
netic disorders. This approach reflects the increasing
likelihood for the explanation of the majority of inherit-
able causes for kidney disease and, in the future, defined
and effective treatments.Abbreviations
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